Independent Financial Group LLC Takes $517,000 Position in Labcorp Holdings Inc. $LH

Independent Financial Group LLC bought a new position in shares of Labcorp Holdings Inc. (NYSE:LH) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 1,936 shares of the medical research company’s stock, valued at approximately $517,000.

A number of other institutional investors have also made changes to their positions in LH. Vanguard Group Inc. increased its holdings in shares of Labcorp by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 9,850,631 shares of the medical research company’s stock valued at $2,471,326,000 after purchasing an additional 37,197 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of Labcorp by 103.1% during the 4th quarter. Victory Capital Management Inc. now owns 5,356,825 shares of the medical research company’s stock worth $1,343,922,000 after buying an additional 2,719,475 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Labcorp by 10.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,204,276 shares of the medical research company’s stock worth $554,728,000 after buying an additional 207,962 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Labcorp by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 2,137,010 shares of the medical research company’s stock worth $534,023,000 after buying an additional 13,775 shares during the period. Finally, Wellington Management Group LLP boosted its holdings in shares of Labcorp by 15.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock worth $604,488,000 after buying an additional 289,029 shares during the period. 95.94% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

LH has been the topic of several research analyst reports. Weiss Ratings reissued a “buy (b-)” rating on shares of Labcorp in a report on Friday, May 8th. Evercore reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a research report on Wednesday, April 8th. Robert W. Baird increased their target price on Labcorp from $335.00 to $338.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Bank of America lifted their price target on Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Finally, Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Nine equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $314.40.

Labcorp Stock Performance

NYSE LH opened at $290.47 on Friday. The firm has a 50-day moving average price of $268.46 and a two-hundred day moving average price of $268.90. Labcorp Holdings Inc. has a 12-month low of $244.52 and a 12-month high of $298.45. The company has a market capitalization of $23.82 billion, a P/E ratio of 25.73, a P/E/G ratio of 1.87 and a beta of 0.89. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68.

Labcorp (NYSE:LH) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $4.09 by $0.16. The company had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the business earned $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Analysts anticipate that Labcorp Holdings Inc. will post 18 earnings per share for the current year.

Labcorp Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Friday, August 28th. Labcorp’s dividend payout ratio (DPR) is 25.51%.

Insider Buying and Selling at Labcorp

In related news, EVP Bryan T. Vaughn sold 234 shares of the business’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total value of $66,968.46. Following the completion of the transaction, the executive vice president owned 6,746 shares of the company’s stock, valued at $1,930,637.74. The trade was a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Kathryn W. Kyle sold 762 shares of the company’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $263.89, for a total transaction of $201,084.18. Following the sale, the executive vice president directly owned 3,813 shares of the company’s stock, valued at $1,006,212.57. This represents a 16.66% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 6,991 shares of company stock valued at $1,796,696 in the last three months. Corporate insiders own 0.84% of the company’s stock.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.